157 related articles for article (PubMed ID: 18805630)
1. Botulinum neurotoxin type A: the poison that can treat the sick.
Novara G
Eur Urol; 2009 Mar; 55(3):560-2. PubMed ID: 18805630
[No Abstract] [Full Text] [Related]
2. Applications of Botulinum toxin in urogynaecology.
Sinha D; Karri K; Arunkalaivanan AS
Eur J Obstet Gynecol Reprod Biol; 2007 Jul; 133(1):4-11. PubMed ID: 17275980
[TBL] [Abstract][Full Text] [Related]
3. Refractory neurogenic detrusor overactivity.
Cruz F; Silva C
Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity.
Lee JC; Yokoyama T; Hwang HJ; Arimitsu H; Yamamoto Y; Kawasaki M; Takigawa T; Takeshi K; Nishikawa A; Kumon H; Oguma K
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):201-11. PubMed ID: 17692094
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Haferkamp A
Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
[No Abstract] [Full Text] [Related]
6. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
Lemack GE
Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
[No Abstract] [Full Text] [Related]
7. In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results.
Kessler TM; Khan S; Panicker JN; Elneil S; Brandner S; Fowler CJ; Roosen A
Eur Urol; 2010 May; 57(5):879-83. PubMed ID: 19765885
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Fowler CJ
Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958
[No Abstract] [Full Text] [Related]
9. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Schurch B
Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956
[No Abstract] [Full Text] [Related]
10. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
[TBL] [Abstract][Full Text] [Related]
11. [Botulinum A toxin in the treatment of patients with detrusor external sphincter dyssynergia and neurogenic low detrusor contractility].
Mazo EB; Krivoborodov GG; Efremov NS
Ter Arkh; 2008; 80(10):49-52. PubMed ID: 19105415
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
Sahai A; Khan MS; Gregson N; Smith K; Dasgupta P;
Nat Clin Pract Urol; 2007 Jul; 4(7):379-86. PubMed ID: 17615549
[TBL] [Abstract][Full Text] [Related]
13. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin a in the overactive bladder: current status and future directions.
Mallina R; Sahai A; Khan MS; Dasgupta P
BJU Int; 2007 Jun; 99(6):1549-50. PubMed ID: 17537223
[No Abstract] [Full Text] [Related]
15. Developments in the pharmacotherapy of the overactive bladder.
Sellers DJ; McKay N
Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263
[TBL] [Abstract][Full Text] [Related]
16. Repeated botulinum toxin injections: a new answer for further questions.
Lazzeri M
Eur Urol; 2007 Dec; 52(6):1571-3. PubMed ID: 17854985
[No Abstract] [Full Text] [Related]
17. Botulinum toxin A in the overactive bladder: current status and future directions.
Dmochowski R; Sand PK
BJU Int; 2007 Feb; 99(2):247-62. PubMed ID: 17313422
[No Abstract] [Full Text] [Related]
18. [Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity].
Perrouin-Verbe B; Ruffion A; Gamé X; Denys P; Kerdraon J; Karsenty G; de Sèze M; Haab F; Saussine C; Soler JM; Amarenco G; Chartier-Kastler E
Prog Urol; 2009 Jun; 19(6):372-82. PubMed ID: 19467455
[TBL] [Abstract][Full Text] [Related]
19. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Apostolidis A; Jacques TS; Freeman A; Kalsi V; Popat R; Gonzales G; Datta SN; Ghazi-Noori S; Elneil S; Dasgupta P; Fowler CJ
Eur Urol; 2008 Jun; 53(6):1245-53. PubMed ID: 18343564
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
